SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Gland Pharma - Quaterly Results

06 Aug 2024 Evaluate
A fair growth of 14.47% in the revenue at Rs. 10120.24 millions was reported in the June 2024 quarter as compared to Rs. 8840.70 millions during year-ago period.Net profit stood at Rs. 2229.21  millions  compared to Rs. 1875.82 millions in the corresponding previous quarter,high by 18.84%.Operating Profit saw a handsome growth to 3420.43 millions from 2945.69 millions in the quarter ended June 2024.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202406 202306 % Var 202406 202306 % Var 202403 202303 % Var
Sales 10120.24 8840.70 14.47 10120.24 8840.70 14.47 41674.28 36165.28 15.23
Other Income 484.90 352.07 37.73 484.90 352.07 37.73 1666.66 2404.64 -30.69
PBIDT 3420.43 2945.69 16.12 3420.43 2945.69 16.12 15754.47 12590.13 25.13
Interest 9.11 15.96 -42.92 9.11 15.96 -42.92 78.43 74.14 5.79
PBDT 3411.32 2929.73 16.44 3411.32 2929.73 16.44 15676.04 11951.38 31.17
Depreciation 408.17 389.82 4.71 408.17 389.82 4.71 1621.07 1467.36 10.48
PBT 3003.15 2539.91 18.24 3003.15 2539.91 18.24 14054.97 10484.02 34.06
TAX 773.94 664.09 16.54 773.94 664.09 16.54 3621.72 2725.76 32.87
Deferred Tax 11.82 75.29 -84.30 11.82 75.29 -84.30 246.84 -27.99 -981.89
PAT 2229.21 1875.82 18.84 2229.21 1875.82 18.84 10433.25 7758.26 34.48
Equity 164.75 164.70 0.03 164.75 164.70 0.03 164.71 164.70 0.01
PBIDTM(%) 33.80 33.32 1.44 33.80 33.32 1.44 37.80 34.81 8.59

Gland Pharma Share Price

1795.80 59.80 (3.44%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×